HSP90B1 and immune system disorder: For instance, small molecule inhibitors targeting HSP90B1 or agents that modulate SYNCRIP’s RNA-binding activity could be explored to simultaneously disrupt metabolic adaptation and correct immune dysfunction in EMs.